Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 1

Conditions

Breast Neoplasms 167Carcinoma, Non-Small-Cell Lung 111Lung Neoplasms 54Hodgkin Disease 22Neoplasm Metastasis 17Recurrence 15Lymphoma 15Triple Negative Breast Neoplasms 14Neoplasms 14Prostatic Neoplasms 10Adenocarcinoma of Lung 10Sarcoma 9Rhabdomyosarcoma 9Uterine Cervical Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 6Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Mesothelioma, Malignant 5Breast Neoplasms, Male 5Brain Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4NSCLC 4Multiple Myeloma 4Unspecified Adult Solid Tumor, Protocol Specific 3Mesothelioma 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Multiple Myeloma × Vinorelbine × Clear all
NCT03442673 2025-03-28

MOCCCA

Insel Gruppe AG, University Hospital Bern

Phase 2 Completed
137 enrolled
Plasma cell

Multiple Myeloma

NCT02791373 2018-04-03

ViGeM

Insel Gruppe AG, University Hospital Bern

Phase 2 Completed
136 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

NCT00477035 2017-01-11

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Stanford University

Phase 1 Completed
22 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Multiple Myeloma

NCT01220375 2014-04-17

PAV

Insel Gruppe AG, University Hospital Bern

Phase 2 Completed
44 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡